---
title: "Genrix Bio released its first-quarter performance, with a net loss attributable to the parent company of 121 million yuan, narrowing the loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237597484.md"
description: "According to the Zhitong Finance APP, Genrix Bio released its first-quarter report for 2025, with the company's first-quarter operating revenue of 20.1558 million yuan; a net loss attributable to shareholders of the listed company of 121 million yuan, with losses narrowing; a net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, of 145 million yuan, with losses narrowing; basic loss per share of 0.33 yuan/share"
datetime: "2025-04-25T14:56:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237597484.md)
  - [en](https://longbridge.com/en/news/237597484.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237597484.md)
---

# Genrix Bio released its first-quarter performance, with a net loss attributable to the parent company of 121 million yuan, narrowing the loss

According to the Zhitong Finance APP, Genrix Bio (688443.SH) released its first-quarter report for 2025, with a revenue of CNY 20.1558 million in the first quarter; a net loss attributable to shareholders of the listed company of CNY 121 million, a narrowed loss; a net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses of CNY 145 million, a narrowed loss; and a basic loss per share of CNY 0.33

### Related Stocks

- [688443.CN](https://longbridge.com/en/quote/688443.CN.md)

## Related News & Research

- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)
- [Australia says Roblox hasn’t fixed its child predator problem](https://longbridge.com/en/news/296523838.md)
- [Soccerment Group Launches Sics Atlas, the First AI-Native Football Platform for Match Analysis and Scouting](https://longbridge.com/en/news/296495845.md)
- [BioInvent says BI-1808 posts promising activity in ongoing Phase 2a cancer trials](https://longbridge.com/en/news/296486934.md)
- [BUZZ-Faeth Therapeutics rises after FDA grants fast-track status for cancer drug](https://longbridge.com/en/news/296104768.md)